Kathrin Jansen named head of Pfizer vaccine R&D

Pfizer ($PFE) has a new vaccines R&D head in Kathrin Jansen, who will begin at the post on June 1. Previously CSO of Pfizer's vaccine research and early development, Jansen will report to global R&D president Mikael Dolsten and work out of Pfizer's Pearl River, NY, research site. "We are building on the rich foundation of our scientific heritage with Prevnar and other vaccines to design and develop vaccine candidates that are unique--and most importantly--with the potential to significantly improve patients' lives," Jansen, one of FierceBiotech's Top Women in Biotech for 2013, said in a release. Her career at Pfizer started when she joined Wyeth in 2006, where she was responsible for leading vaccine research with a focus on infectious diseases, early development and clinical testing. Release | More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.